Evidence of clinical activity for the combination of ceralasertib and anti-PD-L1 therapy (durvalumab) has been observed in multiple Phase II studies and across indications, including non-small cell lung cancer (NSCLC) patients who had progressed on prior anti-PD-(L)1-containing immunotherapy in the HUDSON trial12,13, patients with advanced melanoma14, and advanced gastric cancer15. This evidence concerns the gene CD274 and non-small cell lung carcinoma.